Medicenna Therapeutics Corp (MDNAF)

$0.59 -0.01 (-2.15%)
Market Cap 50.05M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 51,900
Avg Vol 128,934
Day's Range N/A - N/A
Shares Out 83.41M
Stochastic %K 7%
Beta 1.81
Analysts Strong Sell
Price Target $2.96

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting an...

Industry: Biotechnology
Sector: Healthcare
Phone: 416-964-5442
Address:
2 Bloor Street West, Suite 903 7th Floor, Toronto, Canada
Lytnup
Lytnup Aug. 10 at 9:55 PM
$MDNAF David’s latest offering underscores the investment thesis here nicely; would be nice if the industry in fact is moving this way. https://substack.com/@david132748/note/p-210245467?r=10wt7d&utm_medium=ios&utm_source=notes-share-action
0 · Reply
DIJG
DIJG Aug. 7 at 7:16 PM
$MDNAF Big pharma pays for clinical data, not share price. Their acquisition models are built on risk‑adjusted Net Present Value, not market cap. What matters to them is whether a drug can generate real, durable clinical benefit—and whether that benefit can be reproduced at scale. Ability‑1 has already delivered strong signals, but large pharma needs confirmation that these results aren’t a statistical fluke. That’s the purpose of the expanded cohort with readout in H2. If the data hold, MDNA won’t just be another small biotech with a promising molecule—it becomes the goose that lays the golden egg, a late‑stage immunotherapy asset with validated biology and multiple registrational paths. The stock would re-rate accordingly with very high chances of being acquired
1 · Reply
DIJG
DIJG Aug. 7 at 4:22 PM
$MDNAF Today the FDA approved Replimune's drug via the Accelerated Approval ( AA) route based on phase 1/2 data. Replimune’s AA is not just their win—it’s Medicenna’s regulatory green light. If MDNA11’s next dataset matches what has already been reported, the company leaps into • A late stage immunotherapy platform and a top tier acquisition target that big pharma cannot ignore due to having atleast two AA ready programs • A late stage immunotherapy platform with multiple registrational paths
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 6 at 12:09 PM
$MDNAF Sucks they are leaps ahead of us but if they are successful it could actually really help us in the end with early approval, maybe even off ph1/2 data, as our SE profile will be better based on the NHP data, the market seems to forget that 113 achieved >30-fold higher exposure than the α-biased comparator they used!
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 6 at 12:04 PM
$MDNAF Takeda’s IBI363 starts Ph3 today which really validates MDNA113 and the IL-2 program . They got good efficacy in PH2 but with high TREA (like 60% gr3!) hopefully that is because they are alpha based and 113 won’t show the same side effects.
1 · Reply
boomshiva
boomshiva Aug. 5 at 3:29 PM
$MDNAF Is Canada on a holiday again?
3 · Reply
boomshiva
boomshiva Aug. 3 at 5:03 PM
$MDNAF What's up here? I'm not finding anything SP moving in the usual places.
1 · Reply
Witzorwitzout1
Witzorwitzout1 Aug. 1 at 12:28 AM
$MDNAF when can we expect news from that nice Italian group doing the trial
1 · Reply
rudazur2
rudazur2 Jul. 27 at 4:41 PM
$MDNAF at least we can't expect a day like Capricor
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jul. 23 at 7:27 PM
$MDNAF someone tell me this isn’t a POS
2 · Reply
Latest News on MDNAF
No data available.
Lytnup
Lytnup Aug. 10 at 9:55 PM
$MDNAF David’s latest offering underscores the investment thesis here nicely; would be nice if the industry in fact is moving this way. https://substack.com/@david132748/note/p-210245467?r=10wt7d&utm_medium=ios&utm_source=notes-share-action
0 · Reply
DIJG
DIJG Aug. 7 at 7:16 PM
$MDNAF Big pharma pays for clinical data, not share price. Their acquisition models are built on risk‑adjusted Net Present Value, not market cap. What matters to them is whether a drug can generate real, durable clinical benefit—and whether that benefit can be reproduced at scale. Ability‑1 has already delivered strong signals, but large pharma needs confirmation that these results aren’t a statistical fluke. That’s the purpose of the expanded cohort with readout in H2. If the data hold, MDNA won’t just be another small biotech with a promising molecule—it becomes the goose that lays the golden egg, a late‑stage immunotherapy asset with validated biology and multiple registrational paths. The stock would re-rate accordingly with very high chances of being acquired
1 · Reply
DIJG
DIJG Aug. 7 at 4:22 PM
$MDNAF Today the FDA approved Replimune's drug via the Accelerated Approval ( AA) route based on phase 1/2 data. Replimune’s AA is not just their win—it’s Medicenna’s regulatory green light. If MDNA11’s next dataset matches what has already been reported, the company leaps into • A late stage immunotherapy platform and a top tier acquisition target that big pharma cannot ignore due to having atleast two AA ready programs • A late stage immunotherapy platform with multiple registrational paths
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 6 at 12:09 PM
$MDNAF Sucks they are leaps ahead of us but if they are successful it could actually really help us in the end with early approval, maybe even off ph1/2 data, as our SE profile will be better based on the NHP data, the market seems to forget that 113 achieved >30-fold higher exposure than the α-biased comparator they used!
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Aug. 6 at 12:04 PM
$MDNAF Takeda’s IBI363 starts Ph3 today which really validates MDNA113 and the IL-2 program . They got good efficacy in PH2 but with high TREA (like 60% gr3!) hopefully that is because they are alpha based and 113 won’t show the same side effects.
1 · Reply
boomshiva
boomshiva Aug. 5 at 3:29 PM
$MDNAF Is Canada on a holiday again?
3 · Reply
boomshiva
boomshiva Aug. 3 at 5:03 PM
$MDNAF What's up here? I'm not finding anything SP moving in the usual places.
1 · Reply
Witzorwitzout1
Witzorwitzout1 Aug. 1 at 12:28 AM
$MDNAF when can we expect news from that nice Italian group doing the trial
1 · Reply
rudazur2
rudazur2 Jul. 27 at 4:41 PM
$MDNAF at least we can't expect a day like Capricor
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jul. 23 at 7:27 PM
$MDNAF someone tell me this isn’t a POS
2 · Reply
rudazur2
rudazur2 Jul. 22 at 12:51 AM
$MDNAF I've been through some shit, but I never would have bet on this one being the worst 😂
1 · Reply
boomshiva
boomshiva Jul. 20 at 2:01 PM
$MDNAF Jeez louise.
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jul. 13 at 4:51 PM
$MDNAF IMO everything rests on the Neo-Cyt study, do or die. 8 months since an Ability-1 update to me means it’s a bust… and we have zero cash for MDNA-113 I’m hopeful for the neoadjuvent study… if the science on paper plays out in tissue it will be a game changer.
3 · Reply
Pilotboy1985
Pilotboy1985 Jul. 13 at 3:46 PM
$MDNAF increased my position today. I wanted to lower my average since we are hovering at 52 week lows, and I wanted to surpass 20,000 shares. The science is there, the results have been positive, it's just a waiting game but I'm confident we'll be +200% by year end.
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Jul. 13 at 2:47 PM
$MDNAF has a trial in neoadjuvant setting (melanoma) too Noone seems to care... yet... $AGEN
0 · Reply
rudazur2
rudazur2 Jul. 12 at 5:38 PM
$MDNAF 21m marketcap can we see lower ? We have what, 10M$ in cash ?
0 · Reply
Lytnup
Lytnup Jul. 11 at 3:48 PM
$MDNAF Couple of notes while we watch the paint dry. 1). The company is apparently sponsoring this year’s INNOVATE meeting in Naples, to discuss the NEOCYT trial. 2). William Gwynne has accepted the role of Associate Director, Clinical Studies at Medicenna 3). The company filed a Form D on 7/6/26 describing a private placement for roughly $2.34M dated 5-28-26, with just over $250K allocated so far to (3) investors. I am not great at reading these, and SEDAR is down, but I didn’t see pricing, just that it consists of 1 common share and a warrant for 1/2 share (3Y) @ .65. I believe that it’s priced in US dollars. First SEC filing since May 2024. It would seem that things are still happening, albeit at a glacial pace. Best of luck to all MDNAers here - hopefully we hear good news from the fractional CMO on the partnership front.
2 · Reply
OmahaJack
OmahaJack Jul. 8 at 10:41 PM
$MDNAF iIs there hope on the horizon?
2 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jul. 8 at 1:13 AM
$MDNAF Some heavier volume (for us atleast) on both sides of the border… I think something is brewing!
0 · Reply
Lytnup
Lytnup Jul. 7 at 12:05 AM
$MDNAF New Form D - still processing. https://ir.medicenna.com/sec-filings/sec-filing/d/0001807983-26-000003
1 · Reply
NewbJackCity
NewbJackCity Jul. 3 at 3:53 PM
$MDNAF Anyone think we could see 6 week data from NEO-CYT around mid-late July? Not holding my breath. Happy weekend to the brave souls still sticking around 👍🏼
3 · Reply
boomshiva
boomshiva Jul. 1 at 6:11 PM
$MDNAF It's nice to see a return to $0.30XX, but I'm not holding my breath.
1 · Reply